Difference between revisions of "Ticlopidine (Ticlid)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
||
| (One intermediate revision by one other user not shown) | |||
| Line 14: | Line 14: | ||
[[Category:P2Y12 ADP inhibitors]] | [[Category:P2Y12 ADP inhibitors]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2001]] |
Revision as of 19:16, 30 July 2018
General information
Class/mechanism: Irreversible thienopyridine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Also known as
- Brand names: Ticlid, Tilopin